Lyme disease therapeutic - LondonPharma

Drug Profile

Lyme disease therapeutic - LondonPharma

Alternative Names: Artemisinin-based Lyme disease therapeutic - LondonPharma; Lyme disease repurposed therapeutic - LondonPharma

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LondonPharma
  • Class Artemisinins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Lyme disease

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Lyme-disease in United Kingdom (Sublingual, Spray)
  • 26 Nov 2014 Phase-I clinical trials in Lyme disease in United Kingdom (Sublingual) before November 2014
  • 13 Jul 2014 Lyme disease therapeutic - LondonPharma is available for licensing as of 17 Dec 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top